Nutriband Inc. Warrant
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA b… Read more
Nutriband Inc. Warrant (NTRBW) - Net Assets
Latest net assets as of July 2025: $8.49 Million USD
Based on the latest financial reports, Nutriband Inc. Warrant (NTRBW) has net assets worth $8.49 Million USD as of July 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.18 Million) and total liabilities ($1.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.49 Million |
| % of Total Assets | 83.46% |
| Annual Growth Rate | N/A |
| 5-Year Change | -9.6% |
| 10-Year Change | N/A |
| Growth Volatility | 1350.27 |
Nutriband Inc. Warrant - Net Assets Trend (2016–2025)
This chart illustrates how Nutriband Inc. Warrant's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nutriband Inc. Warrant (2016–2025)
The table below shows the annual net assets of Nutriband Inc. Warrant from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-01-31 | $6.43 Million | -0.14% |
| 2024-01-31 | $6.44 Million | -24.90% |
| 2023-01-31 | $8.57 Million | -27.71% |
| 2022-01-31 | $11.86 Million | +66.75% |
| 2021-01-31 | $7.11 Million | +3953.94% |
| 2020-01-31 | $175.43K | -92.70% |
| 2019-01-31 | $2.40 Million | +1878.97% |
| 2018-01-31 | $121.51K | +425.80% |
| 2017-01-31 | $23.11K | +301.47% |
| 2016-01-31 | $-11.47K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nutriband Inc. Warrant's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3843679600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.07K | 0.17% |
| Other Comprehensive Income | $-304.00 | 0.00% |
| Other Components | $44.88 Million | 698.11% |
| Total Equity | $6.43 Million | 100.00% |
Nutriband Inc. Warrant Competitors by Market Cap
The table below lists competitors of Nutriband Inc. Warrant ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Altima Resources Ltd
PINK:ARSLF
|
$5.18 Million |
|
VERU INC. DL-01
F:FMW
|
$5.18 Million |
|
Christina Lake Cannabis Corp
OTCQB:CLCFF
|
$5.18 Million |
|
Nation Group (Thailand) PCL
BK:NATION
|
$5.18 Million |
|
Lease IT Public Company Limited
BK:LIT
|
$5.17 Million |
|
Pontiac Bancorp Inc
PINK:PONT
|
$5.17 Million |
|
Vo2 Cap Holding AB
ST:VO2
|
$5.17 Million |
|
Alpcot Holding AB Series B
ST:ALPCOT-B
|
$5.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nutriband Inc. Warrant's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,438,235 to 6,429,000, a change of -9,235 (-0.1%).
- Net loss of 10,483,000 reduced equity.
- Share repurchases of 149,000 reduced equity.
- New share issuances of 8,406,591 increased equity.
- Other factors increased equity by 2,216,174.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.48 Million | -163.06% |
| Share Repurchases | $149.00K | -2.32% |
| Share Issuances | $8.41 Million | +130.76% |
| Other Changes | $2.22 Million | +34.47% |
| Total Change | $- | -0.14% |
Book Value vs Market Value Analysis
This analysis compares Nutriband Inc. Warrant's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-01-31 | $0.00 | $1.30 | x |
| 2017-01-31 | $0.00 | $1.30 | x |
| 2018-01-31 | $0.02 | $1.30 | x |
| 2019-01-31 | $0.39 | $1.30 | x |
| 2020-01-31 | $0.03 | $1.30 | x |
| 2021-01-31 | $1.06 | $1.30 | x |
| 2022-01-31 | $1.49 | $1.30 | x |
| 2023-01-31 | $1.01 | $1.30 | x |
| 2024-01-31 | $0.81 | $1.30 | x |
| 2025-01-31 | $0.61 | $1.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nutriband Inc. Warrant utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -163.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -489.86%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.16x
- Recent ROE (-163.06%) is above the historical average (-500.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $747.00 |
| 2017 | -654.55% | 0.00% | 0.00x | 1.63x | $-153.57K |
| 2018 | -2198.99% | 0.00% | 0.00x | 1.36x | $-2.68 Million |
| 2019 | -138.54% | -1358.11% | 0.09x | 1.17x | $-3.57 Million |
| 2020 | -1593.22% | -754.10% | 0.17x | 12.53x | $-2.81 Million |
| 2021 | -45.18% | -340.52% | 0.10x | 1.40x | $-3.92 Million |
| 2022 | -71.02% | -592.23% | 0.11x | 1.07x | $-9.61 Million |
| 2023 | -56.12% | -231.33% | 0.22x | 1.10x | $-5.67 Million |
| 2024 | -85.20% | -263.04% | 0.28x | 1.17x | $-6.13 Million |
| 2025 | -163.06% | -489.86% | 0.29x | 1.16x | $-11.13 Million |
Industry Comparison
This section compares Nutriband Inc. Warrant's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nutriband Inc. Warrant (NTRBW) | $8.49 Million | 0.00% | 0.20x | $5.18 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |